SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report
(Date of earliest event reported): June 7, 2004
ARIAD PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware 0-21696 22-3106987
-------- ------- ----------
(State or Other Jurisdiction (Commission File Number) (I.R.S. Employer
of Incorporation) Identification No.)
26 LANDSDOWNE STREET
CAMBRIDGE, MASSACHUSETTS 02139
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code:
(617) 494-0400
ITEM 5. OTHER EVENTS
On June 7, 2004, the Registrant disseminated a Press Release announcing,
for the first time, that sustained anti-tumor activity of its lead
oncology product candidate, AP23573, was demonstrated - as a single
agent - in two phase 1 clinical trials in patients with a broad
spectrum of advanced, refractory and/or metastatic solid tumors. These
initial results were obtained in patients with lung, kidney, bone,
thyroid, liver and soft tissue cancers at well-tolerated dose levels of
drug.
The information contained in the Press Release dated June 7, 2004, is
incorporated herein by reference and attached as Exhibit 99.1 hereto.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits.
99.1 The Registrant's Press Release dated June 7, 2004.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ARIAD PHARMACEUTICALS, INC.
By: /s/ Edward M. Fitzgerald
-------------------------
Edward M. Fitzgerald
Senior Vice President and
Chief Financial Officer
Date: June 7, 2004
EXHIBIT INDEX
-------------
Exhibit Sequential
Number Description Page Number
- ------- ----------- -----------
99.1 The Registrant's Press Release dated June 7, 2004. 4